ÂÜÀòÂÒÂ×

Douglas is founder and Chief Executive Officer of Pneumagen Limited. Founded in April 2016, Pneumagen is developing first-in-class products for the prevention and treatment of infectious disease.

Prior to founding Pneumagen he led the rapid growth of UK-based microbiome company GT Biologics Ltd through its transition into a UK public listing on AIM in February 2014 as part of 4D Pharma PLC (AIM: DDDD).

Previously, amongst other roles, Douglas was at vaccine R&D companies – as CEO at SingVax in Singapore, which was sold to Takeda, and Business Development Director at UK based Microscience Limited which was sold to Emergent in the US.

In the 90s, he was Managing Director of vaccine manufacturer Malta Vaccines Limited.